Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 4	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7	AUG 27	USPATOLD now available on STN
NEWS 8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10	SEP 13	FORIS renamed to SOFIS
NEWS 11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 12	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16	OCT 19	BEILSTEIN updated with new compounds
NEWS 17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 18	NOV 19	WPIX enhanced with XML display format
NEWS 19	NOV 30	ICSD reloaded with enhancements
NEWS 20	DEC 04	LINPADOCDB now available on STN
NEWS 21	DEC 14	BEILSTEIN pricing structure to change
NEWS 22	DEC 17	USPATOLD added to additional database clusters
NEWS 23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 24	DEC 17	DGENE now includes more than 10 million sequences
NEWS 25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 29	JAN 02	STN pricing information for 2008 now available
NEWS 30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

```
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:46:29 ON 23 JAN 2008

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 12:46:39 ON 23 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   22 JAN 2008  HIGHEST RN 1000503-75-2
DICTIONARY FILE UPDATES:  22 JAN 2008  HIGHEST RN 1000503-75-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s vardenafil
L1            4 VARDENAFIL

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     5.61       5.82

FILE 'CAPLUS' ENTERED AT 12:47:08 ON 23 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
```

FILE COVERS 1907 - 23 Jan 2008 VOL 148 ISS 4
FILE LAST UPDATED: 22 Jan 2008 (20080122/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l1 and (hypertension or blood pressure)
<------User Break------>

SEARCH ENDED BY USER

=> s l1
L2          438 L1

=> s l2 and (hypertension or blood pressure)
          92325 HYPERTENSION
            106 HYPERTENSIONS
          92346 HYPERTENSION
                (HYPERTENSION OR HYPERTENSIONS)
<------User Break------>

SEARCH ENDED BY USER

=> s l2 and hypertension
          92325 HYPERTENSION
            106 HYPERTENSIONS
          92346 HYPERTENSION
                (HYPERTENSION OR HYPERTENSIONS)
L3           70 L2 AND HYPERTENSION

=> s l3 and portal
          18470 PORTAL
            380 PORTALS
          18765 PORTAL
                (PORTAL OR PORTALS)
L4            4 L3 AND PORTAL

=> d l4 ibib abs 1-4

L4   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2006:1123280  CAPLUS
DOCUMENT NUMBER:          145:449221
TITLE:                    Roflumilast and roflumilast N-oxide for the treatment
                          of pulmonary hypertension, and combinations
                          with phosphodiesterase 5 inhibitors
INVENTOR(S):              Beume, Rolf; Hatzelmann, Armin; Marx, Degenhard;
                          Schudt, Christian; Tenor, Hermann; Eddahibi, Saadia;
                          Adnot, Serge
PATENT ASSIGNEE(S):       Altana Pharma AG, Germany
SOURCE:                   PCT Int. Appl., 40pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
```

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006111495	A1	20061026	WO 2006-EP61557	20060412
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006237300	A1	20061026	AU 2006-237300	20060412
CA 2604295	A1	20061026	CA 2006-2604295	20060412
EP 1874309	A1	20080109	EP 2006-725734	20060412
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
IN 2007MN01889	A	20071207	IN 2007-MN1889	20071112
KR 2008002950	A	20080104	KR 2007-726282	20071112
PRIORITY APPLN. INFO.:			EP 2005-103147 A	20050419
			WO 2006-EP61557 W	20060412

AB The invention discloses the use of roflumilast, roflumilast-N-Oxide, or a pharmaceutically acceptable salt of either for the treatment of pulmonary hypertension. The invention addnl. discloses the use of roflumilast, roflumilast-N-oxide or a pharmaceutically acceptable salt of either in combination with a phosphodiesterase 5 inhibitor, or a pharmaceutically acceptable salt thereof, for the treatment of pulmonary hypertension.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:149404 CAPLUS
DOCUMENT NUMBER: 144:205821
TITLE: 2-Phenyl-substituted imidazotriazinone derivative phosphodiesterase 5 inhibitors for the treatment of symptoms treatable by increasing cGMP levels
INVENTOR(S): Haning, Helmut
PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006015715	A1	20060216	WO 2005-EP8057	20050723
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,				

SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

DE 102004038328	A1	20060316	DE 2004-102004038328	20040806
AU 2005270446	A1	20060216	AU 2005-270446	20050723
CA 2575907	A1	20060216	CA 2005-2575907	20050723
EP 1776120	A1	20070425	EP 2005-764196	20050723

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR

CN 101035539	A	20070912	CN 2005-80034023	20050723
IN 2007DN01126	A	20070427	IN 2007-DN1126	20070212
KR 2007041613	A	20070418	KR 2007-705245	20070305
NO 2007001231	A	20070503	NO 2007-1231	20070306
US 2007299088	A1	20071227	US 2007-659624	20070905
PRIORITY APPLN. INFO.:			DE 2004-102004038328A	20040806
			WO 2005-EP8057 W	20050723

OTHER SOURCE(S): MARPAT 144:205821

AB The invention relates to the use of PDE 5 inhibitors, and especially of known 2-phenyl-substituted imidazotriazinone derivs., for producing medicaments for the treatment of symptoms that can be treated by increasing cGMP levels in certain tissues, e.g. acute myocardial infarction and damage caused by reperfusion, various symptoms in the female and male reproductive system and urogenital tract, gastrointestinal diseases, damage caused by diabetes, and liver failure.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:1080763 CAPLUS
DOCUMENT NUMBER: 142:16820
TITLE: Use of a phosphodiesterase V inhibitor for the prophylaxis and/or treatment of portal hypertension
INVENTOR(S): Kreisel, Wolfgang
PATENT ASSIGNEE(S): Universitatsklinikum Freiburg, Germany
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004108062	A2	20041216	WO 2004-EP6014	20040603
WO 2004108062	A3	20050310		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10325813	A1	20050105	DE 2003-10325813	20030606

DE 10325813	B4	20071220			
EP 1635838	A2	20060322	EP 2004-739573		20040603
EP 1635838	B1	20070502			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
CN 1871010	A	20061129	CN 2004-80022512		20040603
JP 2006527177	T	20061130	JP 2006-508268		20040603
AT 361074	T	20070515	AT 2004-739573		20040603
ES 2287740	T3	20071216	ES 2004-4739573		20040603
US 2007004744	A1	20070104	US 2006-559694		20060501
PRIORITY APPLN. INFO.:			DE 2003-10325813	A	20030606
			WO 2004-EP6014	W	20040603

AB The invention discloses a medicament for the prophylaxis and/or treatment of diseases or complications associated with portal hypertension, especially hemorrhagic complications. The invention uses a phosphodiesterase V inhibitor, e.g. sildenafil.

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:590998 CAPLUS
DOCUMENT NUMBER: 139:128037
TITLE: Use of acetylcholine esterase antagonists to treat insulin resistance
INVENTOR(S): Lautt, Wayne W.
PATENT ASSIGNEE(S): Diamedica Inc., Can.
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003061648	A1	20030731	WO 2003-CA78		20030127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003235609	A1	20031225	US 2003-350478		20030124
CA 2514088	A1	20030731	CA 2003-2514088		20030127
EP 1471905	A1	20041103	EP 2003-700275		20030127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005519906	T	20050707	JP 2003-561592		20030127
US 2005049293	A1	20050303	US 2004-502066		20041027
PRIORITY APPLN. INFO.:			US 2002-350958P	P	20020125
			WO 2003-CA78	W	20030127

AB A method is provided for reducing insulin resistance in a mammalian subject, comprising administering a suitable acetylcholine esterase antagonist.
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file caplus medline biosis embase
COST IN U.S. DOLLARS SINCE FILE TOTAL

```
                                                    ENTRY    SESSION
FULL ESTIMATED COST                                 19.24      25.06

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)       SINCE FILE      TOTAL
                                                    ENTRY    SESSION
CA SUBSCRIBER PRICE                                 -3.20      -3.20

FILE 'CAPLUS' ENTERED AT 12:51:19 ON 23 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 12:51:19 ON 23 JAN 2008

FILE 'BIOSIS' ENTERED AT 12:51:19 ON 23 JAN 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 12:51:19 ON 23 JAN 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

=> s ("pde 5" or "pde-5" or phosphdiesterase type 5 or phosphodiesterase five or
"phosphodiesterase-5 or vardenafil) and (hypertension or blood pressure)
MISMATCHED QUOTE 'OR "PHOSPHODIE'
Quotation marks (or apostrophes) must be used in pairs,
one before and one after the expression you are setting
off or masking.

=> s ("pde 5" or "pde-5" or phosphdiesterase type 5 or phosphodiesterase five or
"phosphodiesterase-5" or vardenafil) and (hypertension or blood pressure)
   1 FILES SEARCHED...
L5        1365 ("PDE 5" OR "PDE-5" OR PHOSPHDIESTERASE TYPE 5 OR PHOSPHODIESTER
               ASE FIVE OR "PHOSPHODIESTERASE-5" OR VARDENAFIL) AND (HYPERTENSI
               ON OR BLOOD PRESSURE)

=> l5 and portal
L5 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l5 and portal
L6          40 L5 AND PORTAL

=> s l6 and py<=2004
   2 FILES SEARCHED...
L7          10 L6 AND PY<=2004

=> duplicate rem
ENTER L# LIST OR (END):l7
DUPLICATE PREFERENCE IS 'CAPLUS, BIOSIS, EMBASE'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L7
L8           10 DUPLICATE REM L7 (0 DUPLICATES REMOVED)

=> d l8 ibib abs 1-10

L8   ANSWER 1 OF 10  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2004:1080763  CAPLUS
DOCUMENT NUMBER:          142:16820
TITLE:                    Use of a phosphodiesterase V inhibitor for the
                          prophylaxis and/or treatment of portal
                          hypertension
```

INVENTOR(S): Kreisel, Wolfgang
PATENT ASSIGNEE(S): Universitatsklinikum Freiburg, Germany
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004108062	A2	20041216	WO 2004-EP6014	20040603 <--
WO 2004108062	A3	20050310		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10325813	A1	20050105	DE 2003-10325813	20030606
DE 10325813	B4	20071220		
EP 1635838	A2	20060322	EP 2004-739573	20040603
EP 1635838	B1	20070502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1871010	A	20061129	CN 2004-80022512	20040603
JP 2006527177	T	20061130	JP 2006-508268	20040603
AT 361074	T	20070515	AT 2004-739573	20040603
ES 2287740	T3	20071216	ES 2004-4739573	20040603
US 2007004744	A1	20070104	US 2006-559694	20060501
PRIORITY APPLN. INFO.:			DE 2003-10325813 A	20030606
			WO 2004-EP6014 W	20040603

AB The invention discloses a medicament for the prophylaxis and/or treatment of diseases or complications associated with portal hypertension, especially hemorrhagic complications. The invention uses a phosphodiesterase V inhibitor, e.g. sildenafil.

L8 ANSWER 2 OF 10 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2004526367 EMBASE
TITLE: Pulmonary arterial hypertension: Newer treatment are improving outcomes.
AUTHOR: Sirithanakul K.; Mubarak K.K.
CORPORATE SOURCE: Dr. K.K. Mubarak, Wayne State University, 3990 John R, 3937 Hudson, Detroit, MI 48201, United States. mubarak@wayne.edu
SOURCE: Journal of Family Practice, (Dec 2004) Vol. 53, No. 12, pp. 959-969.
Refs: 59
ISSN: 0094-3509 CODEN: JFAPDE
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 015 Chest Diseases, Thoracic Surgery and Tuberculosis
030 Clinical and Experimental Pharmacology
036 Health Policy, Economics and Management
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English

ENTRY DATE: Entered STN: 30 Dec 2004
Last Updated on STN: 30 Dec 2004

L8 ANSWER 3 OF 10 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2005064723 EMBASE
TITLE: Gateways to clinical trials: December 2004.
AUTHOR: Bayes M.; Rabasseda X.; Prous J.R.
CORPORATE SOURCE: M. Bayes, Prous Science, P.O. Box 540, 08080 Barcelona, Spain. mbayes@prous.com
SOURCE: Methods and Findings in Experimental and Clinical Pharmacology, (Dec 2004) Vol. 26, No. 10, pp. 801-827. Refs: 163
ISSN: 0379-0355 CODEN: MFEPDX
COUNTRY: Spain
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 017 Public Health, Social Medicine and Epidemiology
030 Clinical and Experimental Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
006 Internal Medicine
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 24 Feb 2005
Last Updated on STN: 24 Feb 2005

AB Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies Knowledge Area of Prous Science Integrity®, the drug discovery and development portal , http://integrity. prous.com. This issue focuses on the following selection of drugs: Abetimus sodium, ademetionine, agalsidase alfa, agalsidase beta, alemtuzumab, alfimeprase, AMG-162, androgel, anidulafungin, antigastrin therapeutic vaccine, aripiprazole, atomoxetine hydrochloride; Bazedoxifene acetate, bevacizumab, bosentan; Caldaret hydrate, canfosfamide hydrochloride, choriogonadotropin alfa, ciclesonide, combretastatin A-4 phosphate, CY-2301; Darbepoetin alfa, darifenacin hydrobromide, decitabine, degarelix acetate, duloxetine hydrochloride; ED-71, enclomiphene citrate, eplerenone, epratuzumab, escitalopram oxalate, eszopiclone, ezetimibe; Fingolimod hydrochloride, FP-1096; HMR-3339A, HSV-TK/GCV gene therapy, human insulin, HuOKT3gamma1(Ala234-Ala235); Idursulfase, imatinib mesylate, indiplon, InnoVax C insulin glargine, insulin glulisine, irofulven; Labetuzumab, lacosamide, lanthanum carbonate, LyphoDerm, Lyprinol; Magnesium sulfate, metelimumab, methylphenidate hydrochloride; Natalizumab, NO-aspirin; OROS(R); PC-515, pegaptanib sodium, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, pemetrexed disodium, peptide YY3-36, posaconazole, pregabalin, PT-141, pyridoxamine; R-744, ramelteon, ranelic acid distrontium salt, rebimastat, repinotan hydrochloride, rhC1, rhGAD65, rosiglitazone maleate/metformin hydrochloride; Sardomozide, solifenacin succinate; Tadalafil, taxus, telavancin, telithromycin, tenofovir disoproxilfumarate, teriparatide, testosterone transdermal patch, tetomilast, tirapazamine, torcetrapib; Valspodar, vardenafil hydrochloride hydrate, vildagliptin; Yttrium Y90 epratuzumab; Ziprasidone hydrochloride. .COPYRGT. 2004 Prous Science. All rights reserved.

L8 ANSWER 4 OF 10 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2005024582 EMBASE
TITLE: Gateways to Clinical Trials.
AUTHOR: Bayes M.; Rabasseda X.; Prous J.R.
CORPORATE SOURCE: M. Bayes, Prous Science, S.A., P.O. Box 540, 08080 Barcelona, Spain. mbayes@prous.com

SOURCE: Methods and Findings in Experimental and Clinical Pharmacology, (Nov 2004) Vol. 26, No. 9, pp. 723-753. Refs: 195
ISSN: 0379-0355 CODEN: MFEPDX
COUNTRY: Spain
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 016 Cancer
037 Drug Literature Index
038 Adverse Reactions Titles
004 Microbiology: Bacteriology, Mycology, Parasitology and Virology
006 Internal Medicine
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 27 Jan 2005
Last Updated on STN: 6 Sep 2007

AB Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity(R), the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: (PE)HRG214, 1E10, 21-Aminoepothilone B; Ad.Egr.TNF.11D, Ad110-B7.1/HLA, adalimumab, adefovir dipivoxil, alefacept, alemtuzumab, AMD-070, anhydrovinblastine, aripiprazole, asimadoline, atrasentan, AVE-5883; Bimatoprost, BNP-7787, bosentan, botulinum toxin type B, BR-1; Canfosfamide hydrochloride, ciclesonide, curcumin, cypher; D0401, darbepoetin alfa, darifenacin hydrobromide, D-D4FC, dendritic cell-based vaccine, desloratadine, dextrin sulfate, dolastatin 10, drospirenone drospirenone/estradiol, DS-992, duloxetine hydrochloride, dutasteride; E-7010, efalizumab, eletriptan, EM-1421, enfuvirtide, entecavir, etoricoxib, everolimus, exenatide, ezetimibe; Favid, fidarestat, fingolimod hydrochloride, FK-352; Gefitinib, gemifloxacin mesilate, gepirone hydrochloride, gimatecan; HE-2000; Imatinib mesylate, indisulam, insulin detemir, irofulven, ISIS-5132; Lapatinib, levocetirizine, liraglutide, lumiracoxib; Metformin/Glyburide, methionine enkephalin, MK-0431, morphine hydrochloride, motexafin gadolinium, mycobacterium cell wall complex; Naturasone, neridronic acid, nesiritide; Oblimersen sodium, olanzapine/fluoxetine hydrochloride, omalizumab, oral insulin; Paclitaxel poliglumex, PC-515, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, pegvisomant, pexelizumab, picoplatin, pramlintide acetate, prasterone, pregabalin; Quercetin; Ramelteon, ranirestat, RG228, rhGAD65, roflumilast, rubitecan; Sitaxsentan sodium, solifenacin succinate; Tadalafil, taxus, tipifarnib, tolevamer sodium, topixantrone hydrochloride; Valganciclovir hydrochloride, vardenafil hydrochloride hydrate, vildagliptin, voriconazole; XTL-001; Zoledronic acid monohydrate. .COPYRGT. 2004 Prous Science. All rights reserved.

L8 ANSWER 5 OF 10 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2004349672 EMBASE
TITLE: Gateways to Clinical Trials: July/August 2004.
AUTHOR: Bayes M.; Rabasseda X.; Prous J.R.
CORPORATE SOURCE: M. Bayes, Prous Science, S.A., P.O. Box 540, 08080 Barcelona, Spain. mbayes@prous.com
SOURCE: Methods and Findings in Experimental and Clinical Pharmacology, (Jul 2004) Vol. 26, No. 6, pp. 473-503. Refs: 194
ISSN: 0379-0355 CODEN: MFEPDX
COUNTRY: Spain
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 030 Clinical and Experimental Pharmacology

037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 16 Sep 2004
Last Updated on STN: 16 Sep 2004

AB Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity®, the drug discovery and development portal , http://integrity. prous.com. This issue focuses on the following selection of drugs: ABI-007, Ad.Egr.TNF.11D, adefovir dipivoxil, AdPEDF.11, AES-14, albumex, alefacept, alemtuzumab, aliskiren fumarate, alvimopan hydrate, aAminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, anakinra, anti-IL-12 MAb, aprepitant, atazanavir sulfate, atrasentan, avanafil; Banoxantrone, BG-12, bimatoprost, bortezomib, bosentan; Calcipotriol/betamethasone dipropionate, caspofungin acetate, CBT-1, ciclesonide, clofarabine, conivaptan hydrochloride, CpG-7909, C-Vax, Cypher; DA-8159, DAC:GLP-1, darbepoetin alfa, darifenacin, duloxetine hydrochloride; Eculizumab, efalizumab, efaproxiral sodium, EGF vaccine, eletriptan, epratuzumab, erlotinib hydrochloride, escitalopram oxalate, ETC-642, etoricoxib, everolimus, exenatide; Gefitinib, IV gamma-globulin; Human insulin, gamma-hydroxybutyrate sodium; IDN-6556, iguratimod, imatinib mesylate, indiplon, ixabepilone; Laquinimod, LB-80380, lidocaine/prilocaineliraglutide, lopinavir, lopinavir/ritonavir, lucinactant; MAb-14.18, melatonin, MLN-591-DM1; NC-531, neridronic acid, nesiritide, neutrophil-inhibitory factor, niacin/lovastatin niacinllovastatin; Oblimersen sodium, olcegepant, oral Insulin, ORV-105; Palonosetron hydrochloride, PAmAb, pegaptanib sodium, peginterferon alfa-2a, pegvisomant, perifosine, pexelizumab, phenoxodiol, phenserine tartrate, pimecrolimus, pramlintide acetate, pregabalin, PRO-542, prostate cancer vaccine, PT-141; Ramelteon, rasagiline mesilate, rDNA insulin, reslizumab, rh-Lactoferrin, ribamidine hydrochloride, rosuvastatin calcium; S-81841, SC-1, sorafenib, St. John's Wort extract, SU-11248; Taxus, telbivudine, tenofovir disoproxil fumarate, teriparatide, testosterone gel, tezosentan disodium, tipifarnib, tolvaptan, trabectedin, travoprost, travoprost/timolol, treprostinil sodium; Vardenafil hydrochloride hydrate; Xcellerated T cells, XR-5944; Yttrium 90 (90Y) ibritumomab tiuxetan; Ziconotide. .COPYRGT. 2004 Prous Science. All rights reserved.

L8 ANSWER 6 OF 10 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
ACCESSION NUMBER: 2005:356876 BIOSIS
DOCUMENT NUMBER: PREV200510148043
TITLE: Phosphodiesterase-5 (PDE-5) is up-regulated in cirrhotic rat livers; Potential role for PDE-5 inhibitors in reducing the increased intrahepatic vascular tone in cirrhosis.
AUTHOR(S): Loureiro-Silva, Mauricio [Reprint Author]; Iwakiri, Yasuko; Abraldes, Juan G.; Haq, Omar; Groszmann, Roberto J.
CORPORATE SOURCE: Yale Univ, Sch Med, VAMC, New Haven, CT USA
SOURCE: Hepatology, (OCT 2004) Vol. 40, No. 4, Suppl. 1, pp. 271A.
Meeting Info.: 55th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD). Boston, MA, USA. October 29 -November 02, 2004. Amer Assoc Study Liver Dis.
CODEN: HPTLD9. ISSN: 0270-9139.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 14 Sep 2005

Last Updated on STN: 14 Sep 2005

L8 ANSWER 7 OF 10 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2004159928 EMBASE
TITLE: Gateways to Clinical Trials.
AUTHOR: Bayes M.; Rabasseda X.; Prous J.R.
CORPORATE SOURCE: M. Bayes, Prous Science, P.O. Box 540, 08080 Barcelona, Spain. mbayes@prous.com
SOURCE: Methods and Findings in Experimental and Clinical Pharmacology, (Mar 2004) Vol. 26, No. 2, pp. 129-161. Refs: 229
ISSN: 0379-0355 CODEN: MFEPDX
COUNTRY: Spain
DOCUMENT TYPE: Journal; General Review; (Review)
FILE SEGMENT: 030 Clinical and Experimental Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 13 May 2004
Last Updated on STN: 13 May 2004

AB Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies Knowledge Area of Prous Science Integrity(R), the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: Activated protein C concentrate, Ad-CD154, Adeno-Interferon gamma, alemtuzumab, APC-8024, 9-aminocamptothecin, aprepitant, L-arginine hydrochloride, aripiprazole, arsenic trioxide, asimadoline; O6-Benzylguanine, bevacizumab, Bi-20, binodenoson, biphasic insulin aspart, bivatuzumab, 186Re-bivatuzumab, BMS-181176, bosentan, botulinum toxin type B, BQ-123, bryostatin 1; Carboxyamidotriazole, caspofungin acetate, CB-1954, CC-4047, CDP-860, cerivastatin sodium, clevidipine, CTL-102; 3,4-DAP, darbepoetin alfa, decitabine, desloratadine, DHA-paclitaxel, duloxetine hydrochloride; Efalizumab, EGF vaccine, eletriptan, eniluracil, ENMD-0997, eplerenone, eplivanserin, erlosamide, ertapenem sodium, escitalopram oxalate, esomeprazole magnesium, eszopiclone, everolimus, exatecan mesilate, exenatide, ezetimibe; Fondaparinux sodium, FR-901228, FTY-720; Gefitinib, gemtuzumab ozogamicin, gepirone hydrochloride; Hexyl insulin M2, human insulin; Imatinib mesylate, insulin detemir, insulin glargine, iodine (I131) tositumomab, ISV-205, ivabradine hydrochloride, ixabepilone; Levetiracetam, levocetirizine, linezolid, liposomal NDDP, lonafarnib, lopinavir, LY-156735; Mafosfamide cyclohexylamine salt, magnesium sulfate, maxacalcitol, meclinertant, melagatran, melatonin, MENT, mepolizumab, micafungin sodium, midostaurin, motexafin gadolinium; Nesiritide, NS-1209, NSC-601316, NSC-683864; Osanetant; Palonosetron hydrochloride, parecoxib sodium, pegaptanib sodium, peginterferon alfa-2a, peginterferon alfa-2b, pegylated OB protein, pemetrexed disodium, perillyl alcohol, picoplatin, pimecrolimus, pixantrone maleate, plevitrexed, polyglutamate paclitaxel, posurdex, pramlintide acetate, prasterone, pregabalin; Rasburicase, rimonabant hydrochloride, rostaporfin, rosuvastatin calcium; SDZ-SID-791, sibrotuzumab, sorafenib, SU-11248; Tadalafil, targinine, tegaserod maleate, telithromycin, TheraCIM, tigecycline, tiotropium bromide, tipifarnib, tirapazamine, treprostinil sodium; Valdecoxib, Valganciclovir hydrochloride, Vardenafil hydrochloride hydrate; Ximelagatran; Zofenopril calcium, Zoledronic acid monohydrate. .COPYRGT. 2004 Prous Science. All rights reserved.

L8 ANSWER 8 OF 10 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

ACCESSION NUMBER: 2004:286345 BIOSIS
DOCUMENT NUMBER: PREV200400285102

TITLE: Role of phosphodiesterase-5 (PDE5) in altered vascular reactivity in cirrhotic rats.
AUTHOR(S): Sabra, Ramzi [Reprint Author]; Tahseldar-Roumieh, Rima; Ghali, Rana; Tumeh, Yara; El-Hajj, Ihab; Lugnier, Claire
CORPORATE SOURCE: Pharmacology, American University of Beirut, Bliss Strees, Beirut, -, -, Lebanon
rsabra@aub.edu.lb
SOURCE: FASEB Journal, (2004) Vol. 18, No. 4-5, pp. Abst. 643.9. http://www.fasebj.org/. e-file.
Meeting Info.: FASEB Meeting on Experimental Biology: Translating the Genome. Washington, District of Columbia, USA. April 17-21, 2004. FASEB.
ISSN: 0892-6638 (ISSN print).
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 16 Jun 2004
Last Updated on STN: 16 Jun 2004

AB Previous studies showed increased PDE5 activity in kidneys of cirrhotic rats, which might explain the reduced response to natriuretic peptides and the Na retention observed in cirrhosis.We examined if changes in PDE5 can cause altered vascular reactivity in cirrhotic rats. Methods: Cirrhosis was induced by bile duct ligation and excision (BDL). Four weeks after BDL or sham operation (Sham), a concentration response curve fro nitroglycerine (NG) was obtained in endothelium denuded vascular rings from thoracic aortae precontracted with phenylephrine (PE). In some experiments, the rings were pre-incubated with 0.1muM DMPPO, a selective inhibitor of PDE5. In similar experiments, a concentration response curve was ontained for DMPPO. Expression of PDE5 was studied in aortas, kidneys and mesenteric vessels of BDL and Sham rats. Results: The NG curve was right-shifted in BDL rats; pre-incubation with DMPPO enhanced the vasodilator responses in all groups and eliminated the differences in sensitivity between Sham and BDL (see figure). Similarly, the DMPPO concnetration—response curve was right shifted in BDL rats. Expression of PDE5 protein was increased in the aorta and decreased in the mesenteric vasculature in BDL vs. Sham. Conclusions: In cirrhotic animals, the reduced sensitivity of the aortic rings to an NO donor may be explained by higher PDE5 activity in the aorta, leading to a less cGMP levels in response NO (NG). The attenuation of the vasodilator responses to DMPPO and the increased PDE5 expresion in the aorta of BDL rats supports this conclusion. These results may indicate an important role for changes in PDE5 activity in the hemodynamic changes that occur in cirrhosis and portal hypertension; the relation between PDE5 and vasodilation in the splanchnic bed is being explored.Supported by a grant from the Lebanese National Council for Scientific Research.. .

L8 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:590998 CAPLUS
DOCUMENT NUMBER: 139:128037
TITLE: Use of acetylcholine esterase antagonists to treat insulin resistance
INVENTOR(S): Lautt, Wayne W.
PATENT ASSIGNEE(S): Diamedica Inc., Can.
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2003061648	A1	20030731	WO 2003-CA78	20030127 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003235609	A1	20031225	US 2003-350478	20030124 <--
CA 2514088	A1	20030731	CA 2003-2514088	20030127 <--
EP 1471905	A1	20041103	EP 2003-700275	20030127 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005519906	T	20050707	JP 2003-561592	20030127
US 2005049293	A1	20050303	US 2004-502066	20041027
PRIORITY APPLN. INFO.:			US 2002-350958P	P 20020125
			WO 2003-CA78	W 20030127

AB A method is provided for reducing insulin resistance in a mammalian subject, comprising administering a suitable acetylcholine esterase antagonist.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 10 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2003256920 EMBASE
TITLE: Gateways to clinical trials: May 2003.
AUTHOR: Bayes M.; Rabasseda X.; Prous J.R.
CORPORATE SOURCE: M. Bayes, Prous Science, S.A., P.O. Box 540, 08080 Barcelona, Spain. mbayes@prous.com
SOURCE: Methods and Findings in Experimental and Clinical Pharmacology, (May 2003) Vol. 25, No. 4, pp. 317-340. Refs: 143
ISSN: 0379-0355 CODEN: MFEPDX
COUNTRY: Spain
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 030 Clinical and Experimental Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 17 Jul 2003
Last Updated on STN: 17 Jul 2003

AB Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity®, the drug discovery and development portal , http://integrity.prous.com. This issue focuses on the following selection of drugs: 2F5, 2G12, Abetimus sodium, ABI-007, adalimumab, adefovir dipivoxil, AE-941, alefacept, altropane, aminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, aminopterin, anakinra, aprinocarsen sodium, atazanavir, atlizumab, atomoxetine hydrochloride; B7-1 vaccine, bevacizumab, biricodar dicitrate, BMS-188667, brasofensine sulfate, bryostatin 1; Cantuzumab mertansine, CHS-828, cinacalcet hydrochloride, cipamfylline, creatine, CVT-3146; Darbepoetin alfa, DITPA, drotrecogin alfa (activated), duloxetine hydrochloride; Edatrexate, efalizumab, ENMD-0997, epoetin, erlosamide, esomeprazole magnesium, etiprednol dicloacetate, etoricoxib, everolimus, ezetimibe; Fampridine, fenretinide, FTY-720; IGF-I/IGFBP-3 IL-1 cytokine trap, ilodecakin,

interferon beta, ISIS-104838, ISIS-2503, ISIS-5132, ivabradine hydrochloride; Lafutidine, lanthanum carbonate, L-Arginine hydrochloride, LEA29Y, lerdelimumab, levetiracetam, levobupivacaine hydrochloride, levosimendan, lopinavir; Melagatran, mibefradil hydrochloride, miglustat, morphine-6-glucuronide; Nesiritide; Omalizumab, omapatrilat; p24-VLP, parecoxib sodium, peginterferon alfa-2a, peginterferon alfa-2b, pegsunercept, pitavastatin calcium, plevitrexed, prasterone, pregabalin, PRO-2000, prucalopride; Rapacuronium bromide, rebimastat, RGA-0853, rubitecan, ruboxistaurin mesilate hydrate, RWJ-67657; S-16020-2, sarizotan, SLV-306, stiripentol; TA-CIN, tenecteplase, teriparatide, tezacitabine, tipifarnib, trabectedin, troglitazone; Valdecoxib, vardenafil; Z-338, ziconotide. .COPYRGT. 2003 Prous Science. All rights reserved.

=>